- Tytuł:
- Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial
- Autorzy:
- Źródło:
- In The Lancet 13-19 August 2016 388(10045):661-672
Czasopismo naukowe